Trovafloxacin: An overview

Pharmacotherapy

Volumn 19, Issue 1 I, 1999, Pages 21-34

  Garey, Kevin W ^a   Amsden, Guy W ^b  

^a BASSETT HEALTHCARE   (United States)

^b BASSETT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; CEFTAZIDIME; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; FERROUS SULFATE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LOMEFLOXACIN; MEROPENEM; METRONIDAZOLE; MORPHINE; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SUCRALFATE; TEICOPLANIN; TOBRAMYCIN; TROVAFLOXACIN; VANCOMYCIN;

BACTERIAL INFECTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; GONORRHEA; HEADACHE; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY DISORDER; PNEUMONIA; REVIEW; VERTIGO;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; FLUOROQUINOLONES; HUMANS; MULTICENTER STUDIES; NAPHTHYRIDINES;

EID: 0032950644     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.1.21.30507     Document Type: Review

References (67)

1. Blighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997;36(suppl B):1-14.
2. Brighty KE, Gootz TD, Girard TD, et al. 7-(3-azabicycb[3.1.0]hexy)quinolone antibacterial agents: synthesis and biological evaluation resulting in identification of CP-99,219 [abstr]. In: Programs and abstracts of the 33rd interscience conference on antimicrobial agents and chemotherapy, New Orleans. Washington, DC: American Society for Microbiology, 1993.
3. Teng R, Tensfeldt TG, Liston TE, Foulds G. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996;675:53-9.
4. Kato JI, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H. New topoisomerase essential for chromosome segregation in E. coli. Cell 1990;63:393-404.
5. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grIA mutations in stepwise-selected ciprofloxacin-resistant mutants of Stapylococcus aureus. Antimicrob Agents Chemother 1995;39:1554-8.
6. Boswell FJ, Andrews JM, Wise R. Postantibiotic effect of trovafloxacin on Pseudomonas aeruginosa. J Antimicrob Chemother 1997;39:811-14.
7. Spangler SK, Jacobs MR, Appelbaum PC. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.J Antimicrob Chemother 1997;39(suppl B):23-7.
8. Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997;41(7):1594-7.
9. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995;35:230-2.
10. Klugman KP, Gootz TD. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1997;39(suppl B):51-5.
11. Dembry LM, Farrel PA, Orcutt DR, Gerrity LA, Andriole VT. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using standard microdilution broth method and Etest. J Antimicrob Chemother 1997;39(suppl B):35-42.
12. Crokaert F, Aoun M, Duchateau V, Grenier P, Vandermies A, Klastersky J. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. Eur J Clin Microbiol Infect Dis 1996;15:696-8.
13. Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997;39(suppl B):43-9.
14. Shonekan D, Handwerger S, Mildvan D. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria. J Antimicrob Chemother 1997;39:405-9.
15. Endtz HP, Mouton JW, Den Hollander JG, Van Den Braak N, Verbrugh HA. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-postive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob Agents Chemother 1997;41(5):1146-9.
16. Giamarellos-Bourboulis EJ, Grecka R, Galani I, Giamarellou H. Comparative in vitro activity and killing effect of trovafloxacin, DU-6859a, levofloxacin, and sparfloxacin against Staphylococcus aureus. Focus on methicillin-resistant isolates. Clin Drug Invest 1997;14(4):330-6.
17. Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996;40(10):2428-30.
18. Cunha BA, Hussain Qadri SM, Ueno Y, Walters EA, Domenico P. Antibacterial activity of trovafloxacin against nosocomial gram-positive and gram-negative isolates. J Antimicrob Chemother 1997;39(suppl B):29-34.
19. Pfizer, Inc. Trovan (trovafloxacin) package insert. Groton, CT;1998
20. Citron DM, Appleman MD. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intraabdominal infections. Antimicrob Agents Chemother 1997;41(10): 2312-16.
21. Fass RJ, Barnishan J, Solomon MC, Ayers LW. In vitro activities of quinolones, β-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother 1996;40(6):1412-18.
22. Hecht DW, Wexler HM. In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis 1996;23(suppl 1):S2-8.
23. Wexler HM, Molitoris E, Molitoris D, Finegold SM. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother 1996;40(9):2232-5.
24. Hecht DW, Osmolski JR. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media. Clin Infect Dis 1996;23(suppl 1):S44-50.
25. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Villanova, PA: Author, 1997.
26. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 6th ed. Villanova, PA: Author, 1997.
27. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility tests for anaerobic bacteria, 3rd ed. Villanova, PA: Author, 1993.
28. Wiedemann B, Heisig P. Mechanisms of quinolone resistance. Infection 1994;22(suppl 2):S73-9.
29. Gootz, TD, Zaniewski R, Haskell S, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase intravenous mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother 1996;40(12):2691-7.
30. Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer RJ. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers after administration of single intravenous doses of prodrug, alatrofloxacin. J Antimicrob Chemother 1997;39(suppl B):75-80.
31. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996;37:955-63.
32. Kearns GL, Bradley JS, Reed MD, Vincent J. Trovafloxacin (TROV) pharmacokinetics in infants and children [abstr]. In: Programs and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 1997.
33. Arguedas-Mohs A, Vargas SL, Bradley JS, et al. Trovafloxacin CSF penetration and pharmacokinetics (PK) in children [abstr]. In: Programs and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 1997.
34. Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother 1997;39(suppl B):87-92.
35. Wise R, Mortiboy D, Child J, Andrews JM. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996;40(1):47-9.
36. Lacy M, Nicolau D, Nightingale C, et al. The pharmacokinetics of trovafloxacin in patients with AIDS [abstr]. Presented at the annual meeting of the American College of Clinical Pharmacy, Phoenix, Arizona, November 9-12, 1997.
37. Catchpole C, Andrews JM, Woodcock J, Wise R. The comparative pharmacokinetics and tissue penetration of single dose ciprofloxacin 400 mg i.v. and 750 mg p.o. J Antimicrob Chemother 1994;33:103-10.
38. Johnson JH, Cooper MA, Andrews JM, Wise R. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother 1992;36:2444-6.
39. Child J, Boswell F, Brenwald N, Andrews JM, Wise R. The invitro activity of CP-99,219, a new naphthyridone antimicrobial: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995;35:869-76.
40. Andrews JM, Honeybourne D, Brenwald NP, et al. Concentrations of irovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral does to patients undergoing fiber-optic bronchoscopy. J Antimicrob Chemother 1997;39:797-802.
41. Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 08967, a new quinolone derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother 1983;23:559-64.
42. Honeybourne D, Andrews JM, Ashby JP, Lodwick R, Wise R. Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax 1988;43:715-19.
43. Baldwin DR, Wise R, Andrews JM, Gill M, Honeybourne D. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin after oral administration. Respir Med 1993;87:595-601.
44. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. The distribution of temafloxacin in bronchial epithelial lining fluid, alveolar macrophages and bronchial mucosa. Eur Respir J 1992;5:471-6.
45. Cutler NR, Vincent J, Jhee SS, et al. Penetration of trovafloxacin into cerebrospinal fluid in humans after intravenous infusion of alatrofloxacin. Antimicrob Agents Chemother 1997;41(6):1298-1300.
46. Childs S, Gleason D, Immergut M, et al. Penetration of trovafloxacin into prostatic tissue after multiple doses in man [abstr]. In: Programs and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 1997.
47. 18F-labeling and biodistribution of the novel fluoro-quinolone antimicrobial agent, trovafloxacin (CP 99,219). Nucl Med Biol 1996;23(8):995-8.
48. Dalvie DK, Khosla N, Navetta A, Brighty KE. Metabolism of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Drug Metab Dispos 1996;24:1231-40.
49. Deepak KD, Khosla N, Vincent J. Excretion and metabolism of trovafloxacin in humans. Drug Metab Dispos 1997;25(4):423-7.
50. Taylor A, Swan S, Marbury T, et al. The effect of varying degrees of renal impairment on the safety, toleration, and pharmacokinetics of trovafloxacin [abstr]. In: Programs and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 1997.
51. Anderson KE, Egger NG, Goeger DE, et al. The safety, toleration, and pharmacokinetics of trovafloxacin in patients with hepatic impairment [abstr]. In: Programs and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 1997.
52. Graham DR, Klein T, Torres A, et al. A double blind, randomized, multicenter study of nosocomial pneumonia (NOS) comparing trovafloxacin with ciprofloxacin ± clindamycin/metromdazole [abstr]. In: Programs and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 1997.
53. Niederman M, Traub S, Ellison WT, et al. A double blind, randomized, multicenter, global study in hospitalized community acquired pneumonia (CAP) comparing trovafloxacin with ceftriaxone + erythromycin [abstr]. In: Programs and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 1997.
54. Sullivan J, Gezon D, Hopkins W, et al. A double blind, randomized, multicenter study in ambulatory community acquired pneumonia (CAP) comparing trovafloxacin with clarithromycin [abstr]. In: Programs and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 1997.
55. Jones KB, Schwebke J, Thorpe EM Jr, et al. Randomized trial of trovafloxacin and ofloxacin for single-dose therapy of gonorrhea. Am J Med 1998;104:28-32.
56. Hook EW III, Pinson GB, Blalock CJ, Johnson RB. Doseranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea. Antimicrob Agents Chemother 1996;40(7):1720-1.
57. Haria M, Lamb HM. Trovafloxacin. Drugs 1997;54(3):435-45.
58. Mayne JT, Johnson NJ, Kluwe WM, Lencoski DL, Polzer RJ. A study of the phototoxic potential of trovafloxacin in BALB/c mice. J Antimicrob Chemother 1997;39(suppl B):67-73.
59. Teng R, Apseloff G, Vincent J, et al. Effect of trovafloxacin (CP-99,219) on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects [abstr]. Presented at the 36th interscience conference on antimicrobial agents and chemotherapy, New Orleans, September 15-18, 1996.
60. Patterson BE, Kleinermans D, Brown SJ, et al. Effects of orally administered trovafloxacin on the steady-state pharmacokinetics of digoxin: results of a double-blind, placebo-controlled, parallel-group study [abstr]. Presented at the 7th international congress on infectious diseases, Hong Kong, June 10-13, 1996.
61. Lebel M, Teng R, Dogolo LC, et al. The effect of steady-state trovafloxacin on the steady-state pharmacokinetics of caffeine in healthy subjects. Presented at the 36th interscience conference on antimicrobial agents and chemotherapy, New Orleans, September 15-18, 1996.
62. Dickens GR, Wermeling D, Vincent J. Phase I study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men. J Clin Pharmacol 1997;37:248-52.
63. Vincent J, Teng R, Dogolo LC, Willavize SA, Friedman HL. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers, J Antimicrob Chemother 1997;39(suppl B):81-6.
64. Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother 1997;39(suppl B):93-7
65. Patterson BE, Pukins L, Oliver SJ, et al. An open, placebo-controlled, two way crossover study to investigate the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin [abstr]. Presented at the 7th international congress on infectious diseases, Hong Kong, June 10-13, 1996.
66. Teng R, Dogolo LC, Willavize SA, et al. Effect of sucralfate, calcium carbonate, and ferrous sulphate on the bioavailability of trovafloxacin [abstr]. Presented at the 7th international congress on infectious diseases, Hong Kong, June 10-13, 1996.
67. Cardinale V, ed. Drug topics. Red book and updates. Montvale, NJ: Medical Economics, 1997.